What does a coronary calcium score mean? A zero is the clearest answer

A coronary calcium score is a number produced by a short CT scan that measures how much calcified plaque, meaning hardened fatty deposits, has built up in the arteries that feed the heart muscle. Most of its value sits at the bottom of the scale: a score of zero means the scan found no hardened plaque, and in one review of screening studies that group had about 1 cardiovascular event per 100 people over 10 years [6].

A coronary calcium score of 0 is the result the research treats as most informative. A 2020 analysis put the 10-year probability of an event below 5% for people scoring zero, and argued that statin treatment can reasonably be deferred in that group, explicitly setting aside smokers, people with diabetes and people with a family history of early heart disease [14]. That paper also estimated that standard risk calculators misclassify about half the people they place in the borderline-to-intermediate band, which is the gap the scan is meant to close [14].

Above zero, the calcium score range is usually cut at 1 to 99, 100 or more, and 400 or more [15]. Using 6,470 adults from the Multi-Ethnic Study of Atherosclerosis, researchers modelled who would gain more than they lost from preventive aspirin. Among people scoring 100 or above, about 1 cardiovascular event was prevented for every 140 people treated over 5 years, against 1 major bleed for every 518 [15]. At a score of zero the arithmetic ran the other way: roughly 1 event prevented per 1,190 people treated, against 1 major bleed per 567 [15]. These were calculated estimates rather than trial results, and the authors said experimental confirmation is still needed [15].

Who is even eligible for a calcium score test depends on which guideline a doctor follows. Among 1,903 adults aged 55 to 75 who were not already taking statins, in the Dutch Rotterdam Study, the American guideline made 18.3% of men and 11.9% of women eligible for a scan; a different American risk equation dropped that to 13.4% and 3.4%; the European guideline made 46.6% of men and 44.9% of women eligible [5]. Under one rulebook, more than thirteen times as many women qualify as under another. In the people each guideline did select, between 11 and 26 would need 10 years of high-intensity statin treatment to prevent one event [5].

Only one randomised trial has tested acting on the number. It enrolled 365 people aged 40 to 70 across seven Australian hospitals, all without symptoms, all with a close relative who developed coronary disease early, and assigned them either to care informed by their calcium score or to usual care [9]. Over 3 years, plaque volume grew by 24.9 cubic millimetres in the usual-care group and by 15.4 in the score-informed group, and cholesterol fell further in the score-informed group [9]. The trial counted plaque on repeat scans, not heart attacks.

Calcium in a coronary artery is a repair response inside atherosclerotic plaque, the fatty, inflamed build-up in an artery wall. That is why it works as a marker: calcium in these arteries is highly specific to coronary disease rather than a general sign of ageing [7].

Pathology studies have traced how it grows. It starts as microcalcifications, specks between 0.5 and 15 thousandths of a millimetre across, and over years consolidates into fragments and then into sheets wider than 3 millimetres, keeping pace with the plaque itself [8]. The scanner picks up the mineral, and the amount of mineral tracks how long the disease has had to harden.

The same work complicates the idea that more calcium is simply worse. Scattered, spotty calcification has been linked to unstable plaque, the kind that ruptures, while extensive consolidated calcification tends to accompany plaques that are more stable, a pattern also seen alongside statin treatment [8]. In 304 patients who had repeat scans over a median of about six years, calcium that grew denser over time went with fewer cardiovascular events, not more [11].

The score counts hardened plaque and misses soft plaque. The randomised trial needed a second, contrast-enhanced scan to measure the non-calcified plaque volume that a calcium score cannot see [9].

A zero is also not a clean bill of health for everyone. The analysis arguing that statins can be deferred at a score of zero excluded smokers, people with diabetes and people with a family history of premature heart disease from that reasoning [14].

The evidence has narrow edges:

• The only randomised trial of acting on the score enrolled 365 people who all had a family history of early coronary disease, ran for 3 years, and measured plaque volume rather than heart attacks or deaths [9].
• The study on calcium density followed 304 patients, about seven in ten of them men, so it says little about the pattern in women [11].
• The aspirin benefit-and-harm figures were calculated by applying published risk estimates to a cohort, not observed in a trial [15].
• The guideline comparison came from one Dutch cohort aged 55 to 75, none of whom had diabetes [5].
• In type 2 diabetes, the supporting evidence is a review of 21 observational studies rather than randomised trials [2].

The scan carries a radiation dose of about 0.9 to 1.1 millisieverts, the standard unit for measuring a dose of radiation [6]. One paper proposed scanning women aged 55 and over in place of a single screening mammogram so that no extra radiation is added, which is an argument in the literature rather than established practice [14].

Reading a rising score is harder than it sounds. Calcium progression does carry information about risk, but preventive treatment changes how the calcium looks, so a higher number on a repeat scan does not translate directly into worse disease [3].

The scan itself is undemanding: no injection, no treadmill, a few minutes lying still while a CT scanner images the heart between beats, after which software adds up the calcified specks and returns one number [6][7].

Most people will never book one. About 19 million chest CT scans a year in the United States are done for reasons that have nothing to do with the heart, and coronary calcium is visible on many of them. An American Heart Association statement published in 2025 argued for reporting it whenever it shows up, since it adds no radiation, cost or effort [4]. That statement also noted that national guidelines say calcium scoring should be considered for more than 17 million American adults at borderline to intermediate risk, and that take-up has been limited [4].